News in the treatment of AL amyloidosis;Actualités dans le traitement de l'amylose AL

Hematologie

Volumn 18, Issue 2, 2012, Pages 116-123

  Jaccard, Arnaud ^a,b   Mohty, Dania ^a,c   Desport, Estelle ^a,d   Bridoux, Frank ^a,d  

^a Ctr Natl de Ref Pour l'Amylose AL et Autres Maladies Par Depots d'Immunoglobulines Monoclonales   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

AL amyloidosis; Bortezomib; Cardiac biomarker; M Dex

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; BORTEZOMIB;

AMYLOIDOSIS; DISEASE COURSE; HEART AMYLOIDOSIS; HEART DISEASE; HUMAN; PROGNOSIS; REVIEW; SURVIVAL; TREATMENT RESPONSE;

EID: 84861208105     PISSN: 12647527     EISSN: 19506368     Source Type: Journal    
DOI: 10.1684/hma.2012.0692     Document Type: Review

References (41)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59. (Pubitemid 24370135)
2. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998; 82:1501-5. (Pubitemid 28164996)
3. Hoffman J, Jhanwar S, Comenzo RL. AL amyloidosis and progression to multiple myeloma with gain(1q). Br J Haematol 2009; 144:963-4.
4. Leung N, Gunderson H, Tan TS, et al. Melphalan and dexaméthasone Is Less Effective for Patients with Immunoglobulin Light Chain Amyloidosis (AL) with High Bone Marrow Plasmacytosis. ASH Annual Meeting Abstracts 2008 112: 1735.
5. Bochtler T, Hegenbart U, Heiss C, et al. Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated withtranslocation t(11;14). Blood 2011; 117:3809-15.
6. Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009; 94:380-6.
7. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957-9.
8. Neben-Wittich MA, Foote RL, Kalra S. External beam radiation therapy for tracheobronchial amyloidosis. Chest 2007; 132:262-7. (Pubitemid 47068230)
9. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78-84. (Pubitemid 36819341)
10. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010; 3(4):333-42.
11. Mohty D, Pibarot P, Dumesnil JG, et al. Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch Cardiovasc Dis 2011; 104:611-8.
12. Syed IS, Glockner JF, Feng D. et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3:155-64.
13. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751-7. (Pubitemid 41095215)
14. Dietrich S, Schönland SO, Benner A, et al. Treatment with intravenous melphalan and dexaméthasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010; 116:522-8.
15. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-8. (Pubitemid 43726787)
16. Loustaud-Ratti VR, Cypierre A, Rousseau A, et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 2011; 18:19-24.
17. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010; 148:760-7.
18. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010 4; 468(7320):93-7.
19. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone and colchicine versus colchicine only. Am J Med 1996; 100:290-8. (Pubitemid 26111626)
20. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melphalan, prednisone and colchicine. N Engl J Med 1997; 336:1202-7. (Pubitemid 27183649)
21. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88:2801-6. (Pubitemid 26327537)
22. Comenzo RL, Vosburgh E, Falk RH, Comenzo RL, Vosburgh E, Falk RH. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91:3662-70. (Pubitemid 28225733)
23. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19:3350-6. (Pubitemid 32642187)
24. Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118:4346-52.
25. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexaméthasone for AL amyloidosis.NEngl J Med 2007; 357: 1083-93. (Pubitemid 47443213)
26. Jaccard A, Desport E, Leblond V. Autologous stem cell transplantation (ASCT) versus M-Dex in AL amyloidosis: long-term follow-up. Amyloid 2010; 17(Suppl 1): 79-80.
27. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexaméthasone produces long-term remissions in AL amyloidosis. Blood 2007; 110:787-8. (Pubitemid 47105419)
28. Dietrich S, Schönland SO, Benner A, et al. Treatment with intravenous melphalan and dexaméthasone is not able to overcom the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010; 116:522-8.
29. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexaméthasone in systemic AL amyloidosis. Blood 2007; 109:457-64. (Pubitemid 46105938)
30. Wechalekar AD, Kastritis E, Merlini G, Hawkins et al. A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. ASH Annual Meeting Abstracts 2010 116:988.
31. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexaméthasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109:492-6. (Pubitemid 46105943)
32. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lénalidomide with or without dexaméthasone in patients with primary systemic amyloidosis. Blood 2007; 109:465-70. (Pubitemid 46105939)
33. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexaméthasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. Blood 2010; 116:4777-82.
34. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortézomib and dexaméthasone. Haematologica 2007; 92:1351-8. (Pubitemid 350144152)
35. Reece DE, Sanchorawala V, Hegenbart U, et al.Weekly and twiceweekly bortézomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114:1489-97.
36. Wechalekar A, Gillmore J, Lachmann H, Offer M, Hawkins P. Efficacy and safety of bortézomib in systemic AL amyloidosis - a preliminary report. ASH Ann Meet Abstr 2006; 108:29.
37. JA Zonder, V Sanchorawala, RM. Snyder. Rapid haematologic and organ responses in patients with AL amyloid treated with bortézomib plus melphalan and dexaméthasone [Abstract]. Amyloid 2010; 17: OP-084.
38. Penot A, Abraham J, Debarri H, et al. Effectiveness of second line Treatment in AL amyloidosis patient's refractory to M-Dex. Amyloid 2011; 18(suppl 1): 145-7.
39. Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that ProducesvRapid and Complete Hematological Response In Patients with AL Amyloidosis. ASH Annual Meeting Abstracts 2010; 116:3063.
40. Dispenzieri A, Gertz MA, Hayman SR. Pomalidomide and dexaméthasone for previously treated AL: a phase 2 study. Amyloid J Protein Folding Disorders 2010; 17:87.
41. Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine 2008; 87(2):99-109. (Pubitemid 351416775)